Simplex Trading
ANRO icon

Simplex Trading’s Alto Neuroscience ANRO Stock Holding History

Simplex Trading’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Buy
+450
New +$8.34K ﹤0.01% 7351
2025
Q2 		– Sell
-584
Closed -$1.39K – 9918
2025
Q1 		$1K Buy
+584
New +$2.09K ﹤0.01% 8342

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Simplex Trading's ANRO Position: Q1 2026 in Review

Simplex Trading opened a new position in Alto Neuroscience (ANRO) in Q1 2026: 450 shares worth $10.1K. The stake represents ﹤0.01% of the portfolio and ranks #7351 among its holdings. This is a return to the name: Simplex Trading previously reported a position in ANRO as recently as Q1 2025.

Simplex Trading first reported a position in ANRO in Q1 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Simplex Trading held 450 shares of Alto Neuroscience worth $10.1K as of Q1 2026.
  • Alto Neuroscience was a new Simplex Trading position in Q1 2026.
  • Alto Neuroscience made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7351 holding.
  • Simplex Trading first reported a position in Alto Neuroscience in Q1 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.